Antiproteinuric Effect and Transient Reduction in Kidney Function of Calcineurin Inhibitors in Hispanic Patients with Lupus Nephritis

Background: Systemic lupus erythematosus is an autoimmune disease with common renal involvement. Although current remission inital therapies are effective, a high portion of patients suffer flares or are treatment resistant. Combining immunosuppressants with ICNs may improve clinical response, but scarce data exists for the Hispanic population. Methods: Patients with SLE and (LN) with persistent proteinuria despite previous immunosuppression and who began a combined regimen, including CNI, were included. 24-hour proteinuria and eGFR by CKD-EPI were assess at 6 and 12 months. Results: 239 records from patients with LN diagnosis were evaluated, and 42 met inclusion criteria. At 6 months, 40% of the patients obtained complete (CR), and partial response (PR) was reached by 26% of patients. At 12 months, CR and PR were reached by 44% and 32% of patients respectively. A notable reduction in proteinuria was seen at 6 and 12 months compared to baseline (2.89 vs 1.21 g/d, p < 0.001; vs 0.78 g/d, p< 0.001). A transient reduction in eGFR was detected at 6 months (109 vs 104 ml/min/1.73 m2, p= 0.005), which improved significantly at 12 months (109 vs 117 ml/min/1.73 m2, p=0.002). Conclusion: In Hispanic patients with lupus nephritis who previously used immunosuppressor regimes with partial or no response, the addition of a calcineurin inhibitor can be effective. It attains optimal biochemical response rates despite a brief reduction in eGFR that improves without treatment withdrawal. - Women, n (%) 36 (85%) Age, years [± SD] 35 ± 12 ISN/RPS histological classes, n (%) Class V Class III / IV Class III / IV + V 15 (38.5)14 (35.9)10 (25.6) CNI prescribed, n (%) TacrolimusCyclosporine A 34 (81)8 (19) Concomitant immunosuppressor, n (%) Mycophenolate Azathioprine Prednisone 37 (88)5 (12)42 (100) Proteinuria 24 h(g/24h)Basal6 months12 months 2.8 (0.45-13.5)1.2 (0.03-11.1)0.78 (0.04-4.8) Response Combined No response 14 (66%)28 (33%)

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024fh26e1nm
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antiproteinuric Effect and Transient Reduction in Kidney Function of Calcineurin Inhibitors in Hispanic Patients with Lupus Nephritis

Carolina González-Fuentes, Mario Alamilla-Sanchez, Francisco Javier Uribe Rivera, Enrique Fleuvier Morales López et al.
Journal of the American Society of Nephrology
Systemic Lupus Erythematosus Research
article

Antiproteinuric Effect and Transient Reduction in Kidney Function of Calcineurin Inhibitors in Hispanic Patients with Lupus Nephritis

Carolina González-Fuentes, Mario Alamilla-Sanchez, Francisco Javier Uribe Rivera, Enrique Fleuvier Morales López, Martín Benjamín Yamá Estrella, Valeria Yanez Salguero, Irving G. Ramirez, Juan Daniel Diaz Garcia, Karen Hopf
article en

Abstract

Background: Systemic lupus erythematosus is an autoimmune disease with common renal involvement. Although current remission inital therapies are effective, a high portion of patients suffer flares or are treatment resistant. Combining immunosuppressants with ICNs may improve clinical response, but scarce data exists for the Hispanic population. Methods: Patients with SLE and (LN) with persistent proteinuria despite previous immunosuppression and who began a combined regimen, including CNI, were included. 24-hour proteinuria and eGFR by CKD-EPI were assess at 6 and 12 months. Results: 239 records from patients with LN diagnosis were evaluated, and 42 met inclusion criteria. At 6 months, 40% of the patients obtained complete (CR), and partial response (PR) was reached by 26% of patients. At 12 months, CR and PR were reached by 44% and 32% of patients respectively. A notable reduction in proteinuria was seen at 6 and 12 months compared to baseline (2.89 vs 1.21 g/d, p < 0.001; vs 0.78 g/d, p< 0.001). A transient reduction in eGFR was detected at 6 months (109 vs 104 ml/min/1.73 m2, p= 0.005), which improved significantly at 12 months (109 vs 117 ml/min/1.73 m2, p=0.002). Conclusion: In Hispanic patients with lupus nephritis who previously used immunosuppressor regimes with partial or no response, the addition of a calcineurin inhibitor can be effective. It attains optimal biochemical response rates despite a brief reduction in eGFR that improves without treatment withdrawal. - Women, n (%) 36 (85%) Age, years [± SD] 35 ± 12 ISN/RPS histological classes, n (%) Class V Class III / IV Class III / IV + V 15 (38.5)14 (35.9)10 (25.6) CNI prescribed, n (%) TacrolimusCyclosporine A 34 (81)8 (19) Concomitant immunosuppressor, n (%) Mycophenolate Azathioprine Prednisone 37 (88)5 (12)42 (100) Proteinuria 24 h(g/24h)Basal6 months12 months 2.8 (0.45-13.5)1.2 (0.03-11.1)0.78 (0.04-4.8) Response Combined No response 14 (66%)28 (33%)

Journal of the American Society of NephrologyVol. 35(10S)
Centro Medico Nacional Siglo XXI (MX), Centro Médico ABC (MX), Institute for Social Security and Services for State Workers (MX)
Good health and well-being
Openalex Percentile: Top 67%
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.